论文部分内容阅读
目的评价替吉奥(S-1)与卡培他滨术前新辅助化疗对结直肠癌患者外周血细胞角蛋20核糖核酸(CK20mRNA)的表达影响及临床意义。方法收治我院行结直肠癌根治术患者87例,其中术前口服S-1者31例(替吉奥组),口服卡培他滨者26例(卡培他滨组),术前无化疗者30例(对照组),比较3组患者手术当日外周血CK20mRNA的表达水平及阳性率。结果替吉奥、卡培他滨和对照组外周血CK20mRNA阳性率分别为51.6%(16/31),46.2%(12/26)和83.3%(25/30),对照组CK20mRNA阳性率显著高于替吉奥与卡培他滨组(P<0.05),替吉奥与卡培他滨组间差异无统计学意义(P>0.05)。替吉奥、卡培他滨和对照组患者CK20mRNA表达水平分别为(0.15±0.11),(0.14±0.09)和(0.89±0.46),对照组显著高于替吉奥与卡培他滨组(P<0.05),替吉奥与卡培他滨组间差别无统计学意义(P>0.05)。结论结直肠癌患者术前口服替吉奥或卡培他滨可显著降低患者外周血CK20mRNA阳性率及拷贝数。
Objective To evaluate the effect of preoperative neoadjuvant chemotherapy (T-1) and capecitabine on the expression of CK20 mRNA in peripheral blood of patients with colorectal cancer and its clinical significance. Methods Totally 87 patients underwent colorectal cancer radical mastectomy in our hospital, including 31 preoperative oral S-1 patients (for the group of patients), 26 capecitabine patients (capecitabine group), no preoperative Chemotherapy in 30 patients (control group), the expression of CK20mRNA in peripheral blood and the positive rate of the 3 groups were compared. Results The positive rates of CK20 mRNA in peripheral blood of TIGO, Capecitabine and control group were 51.6% (16/31), 46.2% (12/26) and 83.3% (25/30), respectively. The positive rate of CK20 mRNA in control group was significantly higher There was no significant difference between Tegi and Capecitabine in the group of Tegi and Capecitabine (P <0.05). The levels of CK20mRNA in the TIGO, Capecitabine and control groups were (0.15 ± 0.11), (0.14 ± 0.09) and (0.89 ± 0.46), respectively, which were significantly higher in the control group than in the group of the tigetin and capecitabine P <0.05), there was no significant difference between the two groups (P> 0.05). Conclusion Preoperative oral administration of tegaserod or capecitabine in patients with colorectal cancer can significantly reduce the positive rate and copy number of CK20 mRNA in peripheral blood of patients with colorectal cancer.